ISAL 2019 | Update on AMG 330 bispecific for R/R AML

Marion Subklewe

Marion Subklewe, MD, of LMU Hospital Munich, Munich, Germany, discusses the preliminary pharmacokinetic data from the still-recruiting Phase I study of the bispecific CD3/CD33 antibody AMG 330 in relapsed/refractory acute myeloid leukemia (NCT02520427). This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Share this video